A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study
about
Histone modifications, DNA methylation, and schizophreniaEpigenetic treatment of solid tumours: a review of clinical trialsEpigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaEpigenetic regulation in estrogen receptor positive breast cancer--role in treatment responseEpigenetic polypharmacology: from combination therapy to multitargeted drugsCarboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerTARGETgene: a tool for identification of potential therapeutic targets in cancerSynergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.Vorinostat in solid and hematologic malignanciesPhase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Reduced ING1 levels in breast cancer promotes metastasisHistone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Current limitations and future opportunities for epigenetic therapies.Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion.Small-molecular modulators of cancer-associated epigenetic mechanisms.The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone lossCurrent and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Interpreting clinical assays for histone deacetylase inhibitors.Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerGrand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinicRational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancerCombining emerging agents in advanced breast cancerDifferential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Clinical efficacy of vorinostat in a patient with leiomyosarcoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Role of epigenetic modifications in luminal breast cancer.The APC/C Ubiquitin Ligase: From Cell Biology to TumorigenesisSuberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.
P2860
Q24606593-C662FA43-50D9-468B-928F-07E7B099FBF7Q26773803-9AC0BEAB-6CC2-4AB3-9493-112C115A0907Q26783014-0D8BE2F7-B889-4E49-B3E8-63F0712CB25FQ27694612-697DF980-1358-405A-9618-483CDBF3D9C3Q28067666-DF7A5AA5-388D-4D71-BAA1-B99AB0C45AA4Q28265589-7783452D-A369-4720-89D9-92BCD0A80DFEQ28483190-E05F3684-B0F9-4CD9-9C9C-C84442FE3DB5Q30541284-0C958360-975A-4ADF-BFB5-D98D29C62E2AQ33385544-9C713D8D-F06C-4FB4-B411-220D0001AFE3Q33391851-ED54AF76-ABF8-4226-86AC-E785EA34F8C4Q33393266-9E20C6CE-F97D-4328-848A-D4E4AA54CF7AQ33399121-3CC41110-6215-4B13-9D3C-F56B77F3011DQ33429255-E712E2D8-A730-4B84-93E8-AB41A59197FEQ33439519-DF1081C5-EE30-4BF7-9C69-C4A6504B58F8Q33590788-D29A9F79-DE99-4FB4-A6AB-8281325D67F8Q33643334-F3BA350B-1F5E-466B-AB37-9490B5D39832Q33829390-1727397D-3F4B-4EED-9B26-15BAF9A5A47BQ34100927-7ED76AFA-D401-4B1D-A868-58D52F1AAA71Q34171631-22653B9F-3250-4FCB-8AB6-A27AF3032877Q34195077-EC68050E-C19F-4E5D-87B5-5BBE444221F6Q34208585-337B6219-7F6F-447C-9859-DEAAC76FEAD3Q34417159-EDE5D0F3-CFE7-4A51-93AD-9697CCE27857Q34528291-02881932-C027-4500-B1C1-5EDA620A0670Q34584292-6A0D252A-72D5-4B8B-9C5F-CCA69A3AFC8DQ34628002-57EB5D1E-1B3A-4A3B-864C-A4FBD46A8997Q34686787-0A8C2BBE-6BA1-446D-9053-738DF1B8F296Q35000789-1F7AC6F7-AE6C-4BDD-AEDE-55BB548205DFQ35003657-5085C977-0ED3-4602-95E7-569C4026D7DBQ35018496-B08780D0-EB17-4739-8144-B2D900E3B742Q35034708-856E3317-9F4D-48EA-80DC-DFB6F1365F27Q35038016-4B5476BA-15EC-4AF9-B54C-A8227CCB7FC8Q35079955-4FA7855D-4FE2-4DD8-BDED-72C5874B1389Q35584962-0BC7F6EB-B2CF-49CA-8E4F-0E0814EA855AQ35600833-80570B82-1E03-47FD-B030-28BA2BA57D9FQ35687574-45AD9E95-D2BF-4B97-98FC-F30631FB5A9CQ35789686-2D87E8FE-5238-4891-BB61-277B66BFC4BFQ35939690-4F79526B-366D-4237-BED5-175EEDD850E7Q35963443-7783C634-EFE4-4C99-B4B0-C1C067BEDEADQ35971862-B71BFFF9-3296-4AE7-9F4F-ACCC8EC5A9E3Q35994963-8D029A0F-EF67-47BE-BDA0-9DA5081B126D
P2860
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A phase II trial of vorinostat ...... fornia Cancer Consortium study
@ast
A phase II trial of vorinostat ...... fornia Cancer Consortium study
@en
type
label
A phase II trial of vorinostat ...... fornia Cancer Consortium study
@ast
A phase II trial of vorinostat ...... fornia Cancer Consortium study
@en
prefLabel
A phase II trial of vorinostat ...... fornia Cancer Consortium study
@ast
A phase II trial of vorinostat ...... fornia Cancer Consortium study
@en
P2093
P2860
P1476
A phase II trial of vorinostat ...... fornia Cancer Consortium study
@en
P2093
Ana Aparicio
Carol Wong
David D Smith
George Somlo
James H Doroshow
Jana Portnow
Lucille Leong
Mark McNamara
Paul Frankel
P2860
P304
P356
10.1158/1078-0432.CCR-08-0122
P407
P577
2008-11-01T00:00:00Z